Summary
- The Supreme Court has quashed the blacklisting of a medicine supplier for three years, citing state delays in retesting a disputed drug sample.
- The Court emphasized that authorities failed to conduct a mandatory second-laboratory test as required under tender terms, leading to expired batches before retesting could occur.
- This ruling highlights the importance of adhering to procedural requirements in drug testing and supplier evaluations.
- The decision may set a precedent for future cases involving supplier blacklisting and testing protocols in the pharmaceutical industry.
Join the discussion — sign up to comment, upvote, and save articles.